Clinical value and applicability of radiomics in differential diagnosis of dual-phenotype hepatocellular carcinoma and intrahepatic cholangiocarcinoma

Table 1 Comparison of clinical information and imaging features in patients with dual-phenotype hepatocellular carcinoma and those with intrahepatic cholangiocarcinoma

Variable	Training set		Testing set		P value
	t/z or χ2	P value	t/z or χ2	P value
Sex	0.724	0.395	0.047	0.828	0.592
Age	-2.628	0.010	-0.197	0.845	0.676
TBIL	0.458	0.647	0.066	0.947	0.500
ALT	0.409	0.683	-0.104	0.917	0.322
AST	-2.637	0.008	-0.717	0.474	0.254
ALB	-1.013	0.313	-0.913	0.366	0.763
AFP	26.78	0.000	16.544	0.000	0.758
PLT	-0.677	0.499	-0.405	0.685	0.083
HBV	12.510	0.000	2.422	0.120	0.480
Cirrhosis	19.279	0.000	3.878	0.049	0.270
MTD	0.652	0.515	0.038	0.970	0.750
Margin	7.978	0.005	0.007	0.931	0.190
Shape	0.862	0.353	4.561	0.033	0.128
Dense	0.547	0.459	0.476	0.490	0.089
Cholangiectasis	5.872	0.015	0.158	0.691	0.592
Artery within tumor	0.250	0.617	0.011	0.918	0.376
Nonrim APHE	8.801	0.003	2.422	0.119	0.311
Nonperipheral washout	21.524	0.000	2.354	0.125	0.705
Halo sign	1.787	0.181	2.191	0.139	0.612
Capsule	2.433	0.296	1.886	0.389	0.879
Cystoid variation and necrosis	0.358	0.549	3.362	0.067	0.793
Peritumoral enhancement	8.947	0.003	9.477	0.002	0.730

TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALB: Albumin; AFP: Alpha-fetoprotein; PLT: Platelet; HBV: Hepatitis B virus; MTD: Maximum tumor diameter; APHE: Arterial phase hyperenhancement.